Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
-
Published:2022-01
Issue:
Volume:160
Page:100-111
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Schneeweiss Andreas, Michel Laura L., Möbus VolkerORCID, Tesch Hans, Klare Peter, Hahnen Eric, Denkert Carsten, Kast Karin, Pohl-Rescigno Esther, Hanusch Claus, Link Theresa, Untch Michael, Jackisch ChristianORCID, Blohmer Jens-Uwe, Fasching Peter A.ORCID, Solbach Christine, Schmutzler Rita K., Huober Jens, Rhiem Kerstin, Nekljudova ValentinaORCID, Lübbe Kristina, Loibl SibylleORCID
Subject
Cancer Research,Oncology
Reference39 articles.
1. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013;Goldhirsch;Ann Oncol,2013 2. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014 3. Multimodal treatment of locoregionally advanced breast cancer;Hortobagyi;Cancer,1983 4. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial;Hurvitz;Lancet Oncol,2018 5. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer;Minckwitz von;N Engl J Med,2012
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|